Insulin Degludec

Once-weekly insulin efsitora alfa provided similar reductions in HbA1c as once-daily insulin degludec among insulin-naive adults with type 2 diabetes and adults with type 1 diabetes previously receiving a basal and bolus insulin analog.

A novel once-weekly basal insulin conferred noninferior HbA1c reductions compared with daily insulins for insulin-naive adults with type 2 diabetes and those who switched from daily injections, according to topline results from two trials.

A once-weekly basal insulin conferred noninferior reductions in HbA1c among insulin-naive adults with type 2 diabetes and those who receive multiple daily insulin injections, according to top-line results from two phase 3 trials.

Adults with diabetes who use a smart pen for both basal and bolus insulin delivery have a reduction in time in range with each injection they miss over a 14-day period, according to data published in Diabetes Care.

Pregnant women with type 1 diabetes who were treated with insulin degludec had a similar reduction in HbA1c as those using insulin detemir, according to findings published in The Lancet Diabetes & Endocrinology.

Novo Nordisk is the latest company to announce a large reduction in insulin prices as it stated it will cut prices for multiple insulin products by up to 75% in 2024.

Adults with type 1 diabetes using insulin glargine had comparable continuous glucose monitoring metrics at 12 weeks as those who used insulin degludec, according to a presenter.

Adults with type 2 diabetes assigned tirzepatide achieved glycemic targets in a shorter time than those taking 1 mg semaglutide or titrated insulin degludec, according to an analysis of SURPASS-2 and SURPASS-3 data.

A novel once-weekly formulation of basal insulin was safe and effective in adults with long-standing type 2 diabetes, with lower rates of documented and nocturnal hypoglycemia over 32 weeks compared with insulin degludec, phase 2 data show.